Cagrilintide Acetate 10mg

Manufacturer: Dragon Pharma

Pharmaceutical name: Cagrilintide Acetate

Pack: 1 vial (10 mg)

Cagrilintide Acetate is an amylin analog currently being developed alongside the GLP-1 agonist semaglutide to promote long-term weight loss in individuals with overweight and obesity.

 

Amylin, which is released together with insulin from the pancreatic beta cells, triggers a feeling of fullness by acting on both the homeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, suppresses appetite by targeting GLP-1 receptors in the hypothalamus while also enhancing insulin production and decreasing glucagon secretion, which slows gastric emptying. These distinct, yet interconnected mechanisms of the amylin analog and GLP-1 receptor agonist seem to work together to further decrease appetite. Considering the variability and intricate causes of obesity, using a combination therapy that targets multiple biological pathways is a sensible strategy to enhance weight loss results through medication.

 

Cagrilintide Acetate alone, as well as its combination with semaglutide, has exhibited encouraging weight loss outcomes in clinical trials, backing the advancement of this therapy for ongoing weight management.